OB
Orchestra BioMed Holdings, Inc.
OBIO · NASDAQ
$5.95 -6.30% (-$0.40)
1M +17.13%
Market Cap $380.2M
P/E Ratio -
Div. Yield -
ROE 125.93%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 12.92x
P/S 11.89x
P/FFO N/A
Growth
91 /100
Growing Book val. growth 6.45%
Rev. growth 111.62%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 181.36%
Gross margin 99.32%
FCF margin 184.83%
Quality
3 /100
Poor ROA 51.02%
ROIC 56.28%
Asset turnover 0.28x
Debt
54 /100
Moderate Int. coverage -27.37x
Debt/Equity 0.74x
Current ratio 8.26x
Stability
50 /100
Moderate EPS volatility 16.75%
Beta 0.53x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OBIO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Hochman
Employees
86
Headquarters
New Hope
Upcoming events
09 NOV
Earnings
Upcoming earnings report